Abstract 419P
Background
Mammogram is a mandatory screening test for women from 40 years of age in the most parts of the world. While the structural screening for Coronary artery disease doesn’t exist but Women with breast cancer share common risk factors for coronary artery disease (CAD) as well. By using mammogram we can detect the potentially high risk patients, common for both the diseases and this is going to help in long way. Literature suggests that breast arterial classification exist in up to 8- 26% in women undergoing mammogram. In this study we have explored incidence of the total calcifications on mammogram and the percentage of people having Coronary artery diseases in a retrospective to manner.
Methods
It’s a retrospective observation of all mammograms done in past one year for routine screening from three institutes during the study period 2020-2021. Those with calcifications were interviewed and for the willing population we evaluated the coronary artery disease status clinically and radiologically. The mammogram calcifications were classified into mild, moderate, and severe as per the existing literature, so as the findings of the coronary angiogram. The incidence of the calcifications and the presence of CAD in the population were represented as percentages. Medcalc software version 10.1 was used for the analysis.
Results
There are 400 subjects whose complete case records besides the mammograms were available during the study period. Out of these patients 45 had some form of calcifications on mammograms with varying severity. Out of the 45 subjects 38 patients had coronary angiogram testing (either conventional or CT). We could observe 30 of them harboring moderate to severe atherosclerotic changes and varying degree of coronary artery stenosis.
Conclusions
Conclusion The results here hence strongly advocate the radiologists to report the same findings and should prompt the screening physician to encourage the patients for their cardiac risk assessment. In these multi-centre study patients with suspected coronary artery disease, our timely intervention changed the diagnosis and management of patients, who underwent mammogram for screening, but were unaware of the coronary disease, which led to improved outcomes on cardiac aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06